<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Overview of cutaneous lupus erythematosus</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Overview of cutaneous lupus erythematosus</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Overview of cutaneous lupus erythematosus</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Joseph F Merola, MD, MMSc, FAAD, FACR</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">David S Pisetsky, MD, PhD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jeffrey Callen, MD, FACP, FAAD</a></dd><dt><span> </span>Deputy Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Abena O Ofori, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Siobhan M Case, MD, MHS</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Mar 11, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Cutaneous lupus erythematosus (cutaneous LE) includes three categories of LE-specific skin diseases: acute cutaneous lupus erythematosus (ACLE), subacute cutaneous lupus erythematosus (SCLE), and chronic cutaneous lupus erythematosus (CCLE)  (<a class="graphic graphic_table graphicRef93804" href="/z/d/graphic/93804.html" rel="external">table 1</a>). CCLE encompasses discoid lupus erythematosus (DLE), lupus erythematosus tumidus (LE tumidus), lupus profundus (also known as lupus panniculitis), chilblain lupus erythematosus (chilblain LE), and lichenoid cutaneous lupus erythematosus-lichen planus overlap syndrome (LE-LP overlap syndrome).</p><p>Cutaneous LE can occur as a manifestation of systemic lupus erythematosus (SLE) or independent of SLE. The varying strengths of association between SLE and the individual subtypes of cutaneous LE are best illustrated in a graphic  (<a class="graphic graphic_figure graphicRef109668" href="/z/d/graphic/109668.html" rel="external">figure 1</a>). Patients with SLE may also develop a variety of LE-nonspecific skin diseases, cutaneous disorders that lack histologic features of LE, but occur with increased frequency in patients with SLE.</p><p>An overview of the various clinical manifestations of cutaneous LE and LE-nonspecific skin diseases is provided here. In-depth discussions of SLE and the treatment of DLE and SCLE are provided separately. (See  <a class="medical medical_review" href="/z/d/html/4668.html" rel="external">"Clinical manifestations and diagnosis of systemic lupus erythematosus in adults"</a> and  <a class="medical medical_review" href="/z/d/html/13772.html" rel="external">"Initial management of discoid lupus erythematosus and subacute cutaneous lupus erythematosus"</a> and  <a class="medical medical_review" href="/z/d/html/13775.html" rel="external">"Management of discoid lupus erythematosus and subacute cutaneous lupus erythematosus refractory to antimalarial therapy"</a> and  <a class="medical medical_review" href="/z/d/html/4668.html" rel="external">"Clinical manifestations and diagnosis of systemic lupus erythematosus in adults", section on 'Clinical manifestations'</a>.)</p><p class="headingAnchor" id="H131865105"><span class="h1">CLASSIFICATION</span><span class="headingEndMark"> — </span>The modified Gilliam grouping system for cutaneous manifestations of LE provides a helpful organizational framework for the related but distinct clinical entities that comprise LE-specific and LE-nonspecific skin diseases. The three subcategories under LE-specific skin disease and their major clinical variants include: </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Acute cutaneous lupus erythematosus (ACLE)</strong>:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Localized ACLE (ie, malar rash, butterfly rash)</p><p class="bulletIndent2"><span class="glyph">•</span>Generalized ACLE</p><p class="bulletIndent2"><span class="glyph">•</span>Toxic epidermal necrolysis-like ACLE</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Subacute cutaneous lupus erythematosus (SCLE)</strong>:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Annular SCLE</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Papulosquamous SCLE </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Drug-induced SCLE</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Less common variants – Erythrodermic, poikilodermatous, erythema multiforme-like (Rowell syndrome), and vesiculobullous annular SCLE</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Chronic cutaneous lupus erythematosus (CCLE)</strong>:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Discoid lupus erythematosus (DLE):</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Localized DLE</p><p class="bulletIndent3"><span class="glyph">-</span>Generalized DLE</p><p class="bulletIndent3"><span class="glyph">-</span>Hypertrophic DLE</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Lupus erythematosus tumidus (LE tumidus)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Lupus profundus (also known as lupus panniculitis)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Chilblain lupus erythematosus (chilblain LE)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Lichenoid cutaneous lupus erythematosus-lichen planus overlap syndrome (LE-LP overlap syndrome)</p><p></p><p>The key characteristic that unites the LE-specific skin diseases is histopathology. Common shared histopathologic features include a vacuolar interface dermatitis (liquefactive degeneration of the basal layer of the epidermis); hyperkeratosis; epidermal atrophy; a superficial, perivascular, and perifollicular mononuclear cell inflammatory infiltrate; thickening of the basement membrane; and pigment incontinence [<a href="#rid1">1</a>]. All of these features are not necessarily present in all variants. In particular, interface dermatitis is a consistent histopathologic feature of ACLE, SCLE, and discoid lupus erythematosus (the most common form of CCLE) but is not a typical feature of LE tumidus or lupus profundus. Interface dermatitis may also be seen in non-LE disorders, such as dermatomyositis.</p><p>In addition, most LE-specific skin diseases can occur in association with SLE, with the exception of LE tumidus, for which associated SLE is rare  (<a class="graphic graphic_figure graphicRef109668" href="/z/d/graphic/109668.html" rel="external">figure 1</a>). LE-specific diseases may also occur in conjunction with other LE-specific skin diseases and have a similar approach to treatment. (See <a class="local">'Management'</a> below.)</p><p>The designations "acute," "chronic," and "subacute" do not necessarily or strictly reflect the duration of activity of the skin disease. The "acute" in ACLE reflects the often transient and recurrent course of ACLE and the tendency for exacerbations of ACLE to occur during acute flares of SLE; in addition, the terminology was originally coined in reference to a lack of residual long-term skin damage, dyspigmentation, or scarring. The "chronic" in CCLE reflects both the often prolonged course of CCLE and the resulting chronic skin changes of dyspigmentation and scarring that occur in DLE. SCLE may lead to longstanding skin dyspigmentation but typically does not cause scarring.</p><p>Although ACLE, SCLE, and the variants of CCLE are described as distinct entities, patients may develop more than one form of cutaneous LE. Many patients, up to 30 percent in some reports, may have overlap between subsets of cutaneous LE, particularly SCLE and DLE [<a href="#rid2">2</a>].</p><p class="headingAnchor" id="H131865111"><span class="h1">ASSOCIATION WITH SYSTEMIC LUPUS ERYTHEMATOSUS</span><span class="headingEndMark"> — </span>Cutaneous disease is common in systemic lupus erythematosus (SLE); approximately 80 percent of patients develop skin disease at some point in their disease course. However, cutaneous LE frequently exists independently of SLE and may be two to three times more prevalent than SLE [<a href="#rid3">3-6</a>].</p><p>The association with SLE varies among the subtypes of cutaneous LE and mainly has been estimated from cross-sectional studies and retrospective studies [<a href="#rid6">6-8</a>]. Studies evaluating cross-sectional percent prevalence of underlying SLE in patients with cutaneous LE have suggested the following levels of association with SLE (these data do not reflect incident cohort data):</p><p class="bulletIndent1"><span class="glyph">●</span><strong>ACLE </strong>– &gt;90 percent [<a href="#rid3">3</a>]</p><p class="bulletIndent1"><span class="glyph">●</span><strong>SCLE </strong>– 48 to 50 percent [<a href="#rid9">9</a>]</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Localized DLE </strong>– 5 to 10 percent [<a href="#rid10">10</a>]</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Generalized DLE </strong>– 15 to 28 percent [<a href="#rid10">10</a>]</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Lupus profundus/panniculitis </strong>– 5 to 10 percent [<a href="#rid11">11</a>]</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Lupus erythematosus tumidus </strong>– Rarely associated with SLE [<a href="#rid12">12</a>]</p><p></p><p>It is important to again note that these data represent the cross-sectional co-prevalence between cutaneous LE and SLE, rather than a prospective incidence. A graphical representation of the associations between the subtypes of cutaneous LE and SLE is provided  (<a class="graphic graphic_figure graphicRef109668" href="/z/d/graphic/109668.html" rel="external">figure 1</a>).</p><p>Patients who develop SLE after the onset of cutaneous LE often do so within the first few years after diagnosis [<a href="#rid13">13</a>]. In a Danish nationwide cohort study that included 2380 patients with cutaneous LE (62 percent with DLE, 20 percent with SCLE, and the remainder with other or unspecified forms of cutaneous LE), patients who did not have a diagnosis of SLE at the time of diagnosis had a 9 and 13 percent probability of a diagnosis of SLE 5 and 10 years after cutaneous LE, respectively [<a href="#rid13">13</a>]. The median time to diagnosis of SLE was two years. Women and patients with SCLE had the greatest probability for a diagnosis of SLE. The relationships between specific subtypes of CLE with SLE are reviewed in the respective sections below.</p><p class="headingAnchor" id="H131865130"><span class="h1">LUPUS ERYTHEMATOSUS-SPECIFIC SKIN DISEASE</span><span class="headingEndMark"> — </span>Acute cutaneous lupus erythematosus (ACLE), subacute cutaneous lupus erythematosus (SCLE), and chronic cutaneous lupus erythematosus (CCLE) comprise LE-specific skin disease.</p><p class="headingAnchor" id="H3"><span class="h2">Acute cutaneous lupus erythematosus</span><span class="headingEndMark"> — </span>ACLE is a manifestation of systemic lupus erythematosus (SLE) that may present as a characteristic localized facial eruption, less commonly as a generalized eruption, and rarely as a toxic epidermal necrolysis (TEN)-like presentation [<a href="#rid14">14</a>]. Localized ACLE appears in approximately one-half of patients with SLE. Almost all patients with ACLE have SLE:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical manifestations</strong> – The facial eruption of localized ACLE (also known as "malar rash" or "butterfly rash") is characterized by erythema in a malar distribution (cheeks and bridge of the nose)  (<a class="graphic graphic_picture graphicRef75781 graphicRef55875" href="/z/d/graphic/75781.html" rel="external">picture 1A-B</a>). The nasolabial folds are spared.</p><p></p><p class="bulletIndent1">Localized ACLE may precede other symptoms of SLE by months or even years or may be accompanied by other symptoms and signs of acute SLE. The involved skin feels warm and appears slightly edematous. The erythema may last for hours, days, or weeks and often recurs, particularly with sun exposure. In darker skin types, postinflammatory hyperpigmentation or hypopigmentation may persist even after the acute inflammatory stage has resolved.</p><p></p><p class="bulletIndent1">Generalized ACLE presents as an erythematous maculopapular (morbilliform) eruption involving primarily sun-exposed skin. The extensor surfaces of the arms and hands are common sites. Notably, the skin overlying the knuckles often is spared, a feature that contrasts with dermatomyositis. Occasionally, the inflammatory infiltrate is severe enough to produce vesicles or bullae. Severe cases can resemble TEN-like ACLE [<a href="#rid15">15-19</a>]. (See  <a class="medical medical_review" href="/z/d/html/5159.html" rel="external">"Clinical manifestations of dermatomyositis and polymyositis in adults"</a> and  <a class="medical medical_review" href="/z/d/html/2091.html" rel="external">"Stevens-Johnson syndrome and toxic epidermal necrolysis: Pathogenesis, clinical manifestations, and diagnosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Histopathology </strong>– The classic histologic findings of localized and generalized ACLE are consistent with interface dermatitis and include apoptotic keratinocytes, vacuolization of the basal cell layer of the epidermis, a lymphohistiocytic infiltrate in the superficial dermis, and dermal mucin deposition [<a href="#rid20">20</a>]. The findings can be subtle.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Differential diagnosis </strong>– Localized ACLE should be distinguished from rosacea. Rosacea can present with malar erythema and may be exacerbated by sun exposure  (<a class="graphic graphic_picture graphicRef77020" href="/z/d/graphic/77020.html" rel="external">picture 2</a>). Features that favor a diagnosis of rosacea include involvement of the nasolabial fold, papules or pustules (papulopustular variant), and exacerbation of erythema with typical rosacea triggers (spicy foods, caffeine, heat, etc). Although rarely necessary, a skin biopsy can distinguish ACLE from rosacea [<a href="#rid21">21</a>]. (See <a class="local">'Diagnosis'</a> below and  <a class="medical medical_review" href="/z/d/html/13621.html" rel="external">"Rosacea: Pathogenesis, clinical features, and diagnosis"</a>.)</p><p></p><p class="bulletIndent1">Other causes of facial erythema that may be confused with ACLE include sunburn, seborrheic dermatitis, contact dermatitis, erysipelas, flushing (idiopathic or associated with carcinoid syndrome, pheochromocytoma, or mastocytosis), and dermatomyositis. A skin biopsy can aid in distinguishing most of these disorders from ACLE. An exception is dermatomyositis, which exhibits similar pathologic findings. A helpful clinical feature of facial eruptions in dermatomyositis is the tendency to involve the nasolabial folds; in ACLE, the nasolabial folds are spared  (<a class="graphic graphic_picture graphicRef89101" href="/z/d/graphic/89101.html" rel="external">picture 3</a>). (See  <a class="medical medical_review" href="/z/d/html/13686.html" rel="external">"Approach to the patient with facial erythema"</a> and  <a class="medical medical_review" href="/z/d/html/13621.html" rel="external">"Rosacea: Pathogenesis, clinical features, and diagnosis"</a> and  <a class="medical medical_review" href="/z/d/html/5159.html" rel="external">"Clinical manifestations of dermatomyositis and polymyositis in adults"</a>.)</p><p></p><p class="headingAnchor" id="H127905713"><span class="h2">Subacute cutaneous lupus erythematosus</span><span class="headingEndMark"> — </span>SCLE frequently is associated with SLE [<a href="#rid22">22,23</a>]. Approximately 50 percent of affected patients meet the 1997 American College of Rheumatology (ACR) classification criteria for SLE, but subsequent studies have revealed that approximately 10 to 15 percent of patients presenting with SCLE go on to develop severe clinical manifestations of SLE (eg, serious central nervous system or renal disease)  (<a class="graphic graphic_table graphicRef86633" href="/z/d/graphic/86633.html" rel="external">table 2</a>) [<a href="#rid9">9</a>]. SCLE can also occur as a result of drug exposure, and drug-induced SCLE should be considered in all patients presenting with SCLE features. (See  <a class="medical medical_review" href="/z/d/html/4668.html" rel="external">"Clinical manifestations and diagnosis of systemic lupus erythematosus in adults"</a> and <a class="local">'Drug-induced subacute cutaneous lupus erythematosus'</a> below.)</p><p>The ACR classification criteria are known to have inherent limitations, which include classifying SLE too readily in patients with SCLE. Based upon SCLE features alone, at least 3 or 4 of 11 criteria are often met (ie, patients with SCLE may have photosensitivity, positive antinuclear antibodies [SSA/Ro+], mild arthralgias, and/or oral ulcers, which could suggest the diagnosis of SLE). However, these patients may have no other systemic end-organ involvement or other SLE features. In 2012, the Systemic Lupus International Collaborating Clinics (SLICC) proposed revised classification criteria that addressed some of these limitations regarding the cutaneous disease manifestations  (<a class="graphic graphic_table graphicRef86633" href="/z/d/graphic/86633.html" rel="external">table 2</a>). It should be noted that the ACR and SLICC criteria were developed for study purposes and have limited use in clinical practice. (See  <a class="medical medical_review" href="/z/d/html/4668.html" rel="external">"Clinical manifestations and diagnosis of systemic lupus erythematosus in adults", section on 'Classification criteria'</a>.)</p><p>There is a strong association between SCLE, human leukocyte antigen (HLA)-DR3, antibodies to Ro/SSA, and polymorphisms in the tumor necrosis factor (TNF)-alpha promoter gene [<a href="#rid24">24,25</a>]. More than 80 percent of patients with SCLE are positive for anti-Ro/SSA antibodies [<a href="#rid26">26,27</a>]. SCLE has also been associated with homozygous deficiencies of the second component of complement [<a href="#rid28">28,29</a>] (see  <a class="medical medical_review" href="/z/d/html/1818.html" rel="external">"The anti-Ro/SSA and anti-La/SSB antigen-antibody systems"</a>):</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical manifestations </strong>– SCLE begins as small, erythematous, slightly scaly papules that evolve into either psoriasiform plaques (papulosquamous SCLE) or annular plaques (annular SCLE)  (<a class="graphic graphic_picture graphicRef55903 graphicRef66580" href="/z/d/graphic/55903.html" rel="external">picture 4A-B</a>). The latter often coalesce to form polycyclic or figurative patterns. The plaques are typically erythematous with variable amounts of overlying scale. The most common sites of involvement are somewhat photodistributed and include the shoulders, forearms, neck, and upper torso. Despite a photoaggravated nature of the condition, the face is often spared [<a href="#rid23">23</a>]. Dyspigmentation at sites of resolved SCLE is common and may resemble vitiligo. Scarring usually does not occur. Less common variants include vesiculobullous annular, poikilodermatous, erythrodermic, and erythema multiforme-like (Rowell syndrome) SCLE. Drug-induced SCLE is reviewed separately. (See <a class="local">'Drug-induced subacute cutaneous lupus erythematosus'</a> below.)</p><p></p><p class="bulletIndent1">Most patients with SCLE exhibit photosensitivity, with exacerbations of disease stimulated by sun exposure. A case-control study of 76 patients with SCLE (including 48 who also fulfilled ACR criteria for SLE) and 24 patients with SLE without SCLE found photosensitivity nearly twice as prevalent in patients with SCLE than in patients with SLE without SCLE (86 versus 46 percent, respectively) [<a href="#rid30">30</a>]. Associated arthralgias and oral ulcers are reported; however, serious features such as cytopenias and serositis occur much less frequently. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Histopathology </strong>– Compared with discoid lupus erythematosus (DLE), the histopathology of SCLE shows less follicular plugging and hyperkeratosis, and the perivascular and appendageal lymphocytic infiltrates tend to be more superficial. There is vacuolization of the basement membrane and mucin deposition in the dermis. Basement membrane thickening is generally absent or minimal  (<a class="graphic graphic_picture graphicRef51438 graphicRef65220" href="/z/d/graphic/51438.html" rel="external">picture 5A-B</a>) [<a href="#rid23">23,31</a>]. (See <a class="local">'Discoid lupus erythematosus'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Differential diagnosis</strong> – The differential diagnosis of SCLE includes other disorders that may exhibit erythematous papules or plaques such as psoriasis, tinea corporis, nummular eczema, dermatomyositis, cutaneous T cell lymphoma, and drug eruptions [<a href="#rid32">32</a>]. If the diagnosis is uncertain, a biopsy can distinguish SCLE. (See <a class="local">'Diagnosis'</a> below.)</p><p></p><p class="headingAnchor" id="H203911101"><span class="h3">Drug-induced subacute cutaneous lupus erythematosus</span><span class="headingEndMark"> — </span>Many classes of drugs have been implicated in SCLE, including antihypertensive drugs, lipid-lowering agents, proton pump inhibitors, antifungal agents, TNF-alpha inhibitors, and others  (<a class="graphic graphic_table graphicRef62265" href="/z/d/graphic/62265.html" rel="external">table 3</a>) [<a href="#rid10">10,33-36</a>]. A case-control study that included 234 patients with incident SCLE found that more than one-third of cases appeared related to a drug exposure [<a href="#rid33">33</a>]. (See  <a class="medical medical_review" href="/z/d/html/4677.html" rel="external">"Drug-induced lupus", section on 'Subacute cutaneous lupus erythematosus'</a>.)</p><p>Drug-induced SCLE and idiopathic SCLE have similar clinical, histopathologic, and laboratory features and can be indistinguishable in the absence of a helpful medication history. However, certain features may be more likely to occur in each subtype. Widespread disease, including lesions outside of photo-exposed areas, bullous or erythema multiforme-like lesions, and vasculitic-appearing lesions, may favor a diagnosis of drug-induced SCLE over idiopathic SCLE [<a href="#rid27">27</a>].</p><p>In addition, a retrospective study of 165 patients with idiopathic SCLE and 67 patients with drug-induced SCLE found that, compared with patients with idiopathic SCLE, patients with drug-induced SCLE were older (mean age 41 versus 53 years), reported more systemic symptoms (13 versus 48 percent), and were more likely to have leukocytoclastic vasculitis on histopathology (0 versus 11 percent) [<a href="#rid37">37</a>]. Findings that were more common in idiopathic disease than in drug-induced disease included histopathology showing mucin deposition (70 versus 36 percent) and direct immunofluorescence findings of both immunoglobulin M (IgM) and C3c deposition at the dermoepidermal junction (52 versus 21 percent). Tissue eosinophilia does not help to distinguish idiopathic from drug-induced SCLE [<a href="#rid38">38</a>].</p><p>Drug withdrawal often leads to improvement in drug-induced SCLE. In the retrospective study of 11 patients with drug-induced SCLE and 79 patients with idiopathic SCLE, all cases of drug-induced disease resolved after drug withdrawal. The mean time to resolution was seven weeks and Ro/SSA antibodies eventually disappeared in 8 of the 10 patients who previously tested positive for these antibodies [<a href="#rid27">27</a>]. Similarly, most patients in a retrospective study of 15 patients with drug-induced SCLE experienced improvement in the clinical manifestations of SCLE within eight weeks of drug withdrawal and a decrease in anti-Ro/SSA antibodies within eight months following drug withdrawal [<a href="#rid34">34</a>].</p><p class="headingAnchor" id="H1672756207"><span class="h3">Neonatal lupus</span><span class="headingEndMark"> — </span>Neonatal lupus shares a variety of features with classic SCLE; therefore, some clinicians consider the cutaneous manifestations of this entity a subtype of SCLE. Similarities with classic SCLE include clinical features (arcuate erythematous plaques that resolve without scarring  (<a class="graphic graphic_picture graphicRef51166" href="/z/d/graphic/51166.html" rel="external">picture 6</a>)), histologic findings (interface dermatitis), and an association with anti-Ro/SSA antibodies. (See <a class="local">'Neonatal lupus'</a> below and  <a class="medical medical_review" href="/z/d/html/6402.html" rel="external">"Neonatal lupus: Epidemiology, pathogenesis, clinical manifestations, and diagnosis"</a>.)</p><p class="headingAnchor" id="H127906432"><span class="h2">Chronic cutaneous lupus erythematosus</span><span class="headingEndMark"> — </span>CCLE includes:</p><p class="bulletIndent1"><span class="glyph">●</span>Discoid lupus erythematosus (DLE)</p><p class="bulletIndent1"><span class="glyph">●</span>Lupus erythematosus tumidus (LE tumidus)</p><p class="bulletIndent1"><span class="glyph">●</span>Lupus profundus (lupus panniculitis)</p><p class="bulletIndent1"><span class="glyph">●</span>Chilblain lupus erythematosus (chilblain LE)</p><p class="bulletIndent1"><span class="glyph">●</span>Lichenoid cutaneous lupus erythematosus-lichen planus overlap syndrome (LE-LP overlap syndrome)</p><p></p><p>The most common type of CCLE is DLE, accounting for 73 to 85 percent of CCLE [<a href="#rid7">7,39</a>].</p><p class="headingAnchor" id="H4"><span class="h3">Discoid lupus erythematosus</span><span class="headingEndMark"> — </span>It is estimated that 15 to 30 percent of patients with SLE develop DLE [<a href="#rid1">1,40,41</a>]. Patients with localized or generalized DLE are estimated to have cross-sectional prevalences of concurrent SLE between 5 and 28 percent. (See <a class="local">'Association with systemic lupus erythematosus'</a> above.)</p><p>The presence of DLE lesions among patients with SLE may modify the risk of specific SLE features. Compared with SLE patients without DLE, those with DLE have increased risk for photosensitivity and leukopenia but decreased risk for serositis and arthritis. There is no obvious change in risk of nephritis despite variable reports of a "renal-protective effect" of the presence of discoid lesions among SLE patients [<a href="#rid42">42,43</a>].</p><p>Data on the risk for progression of DLE to SLE are limited to retrospective cohort studies, studies lacking power to detect statistical significance of potential markers of progression, and studies that do not address DLE specifically as a CLE subset. In these studies, progression to SLE has occurred in 0 to 28 percent of patients initially presenting with DLE [<a href="#rid7">7,13,41,44</a>]. Risk factors for progression include an increasing number of clinical and serologic features of SLE: more widespread DLE lesions, arthralgias and arthritis, high antinuclear antibody (ANA) titers, leukopenia, and high erythrocyte sedimentation rates [<a href="#rid10">10,45,46</a>].</p><p>Progression to SLE appears to occur most often in the first few years after a DLE diagnosis. A Swedish-based, population, cohort study of 1088 patients with CLE (including 868 with DLE) found that patients with DLE and no preceding diagnosis of SLE (n = 656) had a 10 percent probability of getting a new SLE diagnosis within one year and had a 17 percent probability of getting an SLE diagnosis within three years [<a href="#rid8">8</a>]. In addition, several retrospective studies have found that the majority of patients who progress from DLE to SLE progress within five years [<a href="#rid10">10,47</a>]. One retrospective study of 32 patients who progressed from DLE to SLE found a median time to progression from DLE to SLE of approximately 1.2 years [<a href="#rid47">47</a>].</p><p>It is worth noting that patients with DLE and other mucocutaneous manifestations of LE may meet ACR classification criteria for SLE without having other end-organ disease [<a href="#rid48">48</a>]. Revised classification criteria (the SLICC criteria) have been proposed to address some limitations of the ACR criteria (see  <a class="medical medical_review" href="/z/d/html/4668.html" rel="external">"Clinical manifestations and diagnosis of systemic lupus erythematosus in adults", section on 'Classification criteria'</a>):</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical manifestations </strong>– The classic findings of DLE are discrete, erythematous, somewhat indurated plaques covered by a well-formed adherent scale that extends into dilated hair follicles (follicular plugging). The plaques tend to expand slowly with active inflammation at the periphery and then heal, leaving depressed central scars, atrophy, telangiectasias, and hyperpigmentation and/or hypopigmentation [<a href="#rid45">45</a>]. DLE most often involves the face, neck, and scalp but may also occur on the ears (particularly conchal bowls) and, less frequently, on the upper torso  (<a class="graphic graphic_picture graphicRef75833 graphicRef64844 graphicRef72588 graphicRef53535" href="/z/d/graphic/75833.html" rel="external">picture 7A-D</a>). Localized DLE is limited to sites above the neck. Generalized DLE refers to DLE occurring both above and below the neck. Published classification criteria for DLE emphasize these clinical features [<a href="#rid49">49</a>].</p><p></p><p class="bulletIndent1">Hypertrophic DLE is an uncommon clinical variant of DLE characterized by the development of hyperkeratotic, verrucous plaques [<a href="#rid50">50</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Histopathology </strong>– Pathologic examination of DLE typically reveals hyperkeratosis, follicular plugging, basal layer vacuolar changes, and a mononuclear cell infiltrate (predominantly T cells) near the dermal-epidermal junction, dermal blood vessels, and appendages  (<a class="graphic graphic_picture graphicRef81453" href="/z/d/graphic/81453.html" rel="external">picture 8</a>) [<a href="#rid31">31</a>]. The basement membrane is usually thickened, a change that is best appreciated with a periodic acid-Schiff (PAS) stain, and there is dermal mucinosis. Although immunofluorescence microscopy may be positive in cutaneous LE, its use is limited by false-positive results on sun-exposed skin and by negative results in longstanding chronic LE lesions. (See <a class="local">'Direct immunofluorescence (lupus band test)'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Differential diagnosis </strong>– The clinical differential diagnosis of DLE includes:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Tinea faciei</p><p class="bulletIndent2"><span class="glyph">•</span>Granuloma faciale  (<a class="graphic graphic_picture graphicRef50769 graphicRef94613" href="/z/d/graphic/50769.html" rel="external">picture 9A-B</a>) </p><p class="bulletIndent2"><span class="glyph">•</span>Sarcoidosis</p><p class="bulletIndent2"><span class="glyph">•</span>Lupus vulgaris (cutaneous tuberculosis)</p><p class="bulletIndent2"><span class="glyph">•</span>Lymphoproliferative disorders of skin (benign or malignant)</p><p class="bulletIndent2"><span class="glyph">•</span>Cutaneous leishmaniasis (eg, lupoid leishmaniasis, leishmaniasis recidivans)</p><p class="bulletIndent2"><span class="glyph">•</span>Tuberculoid leprosy</p><p></p><p class="bulletIndent1">Verrucous/hypertrophic discoid lupus may be confused with hypertrophic lichen planus, keratoacanthoma, squamous cell cancer, and prurigo nodularis. (See <a class="local">'Diagnosis'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Risk for squamous cell carcinoma</strong> – Infrequently, squamous cell carcinoma develops in sites of DLE. Squamous cell carcinoma in DLE is estimated to occur in 2 to 3 percent of DLE patients, is postulated to be related to the presence of chronic inflammation, and is associated with increased risk for a poor prognosis for squamous cell carcinoma [<a href="#rid51">51</a>].</p><p></p><p class="headingAnchor" id="H203914494"><span class="h3">Less common subtypes</span><span class="headingEndMark"> — </span>LE tumidus, lupus profundus (lupus panniculitis), chilblain LE, and lupus erythematosus-lichen planus (LE-LP) overlap syndrome are additional manifestations of CCLE.</p><p class="headingAnchor" id="H127906826"><span class="h4">Lupus erythematosus tumidus</span><span class="headingEndMark"> — </span>Although often categorized as a form of LE-specific skin disease, the rarity of association with concurrent SLE and the lack of interface dermatitis on pathology have raised debate about where LE tumidus falls in the classification of cutaneous lupus disorders. In a series of 40 patients with LE tumidus, only 10 percent were ANA-positive [<a href="#rid52">52</a>]. An increased incidence among smokers has been noted [<a href="#rid53">53</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical manifestations </strong>– LE tumidus is characterized by photodistributed, chronic, pink to violaceous, urticarial or edematous plaques or nodules [<a href="#rid52">52,54,55</a>]. Annular plaques may occur  (<a class="graphic graphic_picture graphicRef94614 graphicRef94615" href="/z/d/graphic/94614.html" rel="external">picture 10A-B</a>). Scale and scarring are absent.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Histopathology </strong>– There is a moderate to dense, superficial and deep, perivascular lymphocytic infiltrate, consisting of predominately CD3<sup>+</sup>/CD4<sup>+</sup> lymphocytes. In addition, there is mucin deposition in the papillary and reticular dermis. Interface changes at the dermal-epidermal junction are absent in most cases. A minority of patients exhibit focal interface changes [<a href="#rid54">54</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Differential diagnosis </strong>– The differential diagnosis of LE tumidus includes causes of erythematous to violaceous plaques with absent surface change, such as benign lymphocytic infiltration of skin (Jessner's disease), polymorphous light eruption, pseudolymphoma, B cell lymphoma, plaque mucinosis, and solar urticaria. (See <a class="local">'Diagnosis'</a> below.)</p><p></p><p class="headingAnchor" id="H127906839"><span class="h4">Lupus profundus (lupus panniculitis)</span><span class="headingEndMark"> — </span>Lupus profundus (also known as lupus panniculitis) is an uncommon form of CCLE. Coexistent DLE occurs in at least one-third of patients with lupus profundus; SLE is present in approximately 10 percent of patients [<a href="#rid11">11,56</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical manifestations </strong>– Lupus profundus presents as indurated plaques or nodules with or without overlying cutaneous changes [<a href="#rid57">57</a>]. The plaques or nodules may appear on the scalp, face, upper arms, chest (particularly breasts), lower back, flank, upper thighs, or buttocks and are often tender or painful. Infrequently, patients develop ulceration or calcifications at sites of involvement. Upon resolution, lupus profundus may leave depressed areas of lipoatrophy  (<a class="graphic graphic_picture graphicRef83791" href="/z/d/graphic/83791.html" rel="external">picture 11</a>).</p><p></p><p class="bulletIndent1">Lesions involving the breast may be initially concerning for breast malignancy, including an atypical appearance with calcification on mammography; this presentation has been referred to as "lupus mastitis" [<a href="#rid58">58</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Histopathology </strong>–<strong> </strong>Histopathologic examination reveals perivascular infiltrates of mononuclear cells plus panniculitis, manifested as hyaline fat necrosis with mononuclear cell infiltration and lymphocytic vasculitis  (<a class="graphic graphic_picture graphicRef80683 graphicRef59536" href="/z/d/graphic/80683.html" rel="external">picture 12A-B</a>). The presence of immune deposits in the dermal-epidermal junction on direct immunofluorescence offers support for the diagnosis [<a href="#rid59">59</a>]. (See <a class="local">'Diagnosis'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Differential diagnosis</strong> – Nodules of lupus profundus on the breast may raise concern for a breast malignancy. The possibility of subcutaneous panniculitis-like T cell lymphoma, which often manifests with subcutaneous nodules or plaques on the trunk or extremities, also should be considered [<a href="#rid60">60</a>]. A biopsy will distinguish lupus profundus from these entities. (See <a class="local">'Diagnosis'</a> below.)</p><p></p><p class="headingAnchor" id="H107130624"><span class="h4">Chilblain lupus erythematosus</span><span class="headingEndMark"> — </span>Chilblain LE is diagnosed in patients with clinical findings of pernio (also known as chilblains) in conjunction with clinical or laboratory features of cutaneous or systemic LE. Approximately 25 percent of patients who present with pernio meet classification criteria for SLE, and additional patients (5 to 6 percent in one study) may fulfill SLE criteria subsequently [<a href="#rid61">61</a>]. (See  <a class="medical medical_review" href="/z/d/html/13758.html" rel="external">"Pernio (chilblains)"</a>.)</p><p>Similar to idiopathic pernio, chilblain LE presents with tender, bright red to reddish-blue papules, nodules, or plaques on the toes, fingers, nose, or ears precipitated by cold exposure  (<a class="graphic graphic_picture graphicRef56419" href="/z/d/graphic/56419.html" rel="external">picture 13</a>) [<a href="#rid62">62</a>]. Nodules on acral areas may ulcerate. Chilblain LE is reviewed separately. (See  <a class="medical medical_review" href="/z/d/html/13758.html" rel="external">"Pernio (chilblains)", section on 'Chilblain lupus erythematosus'</a>.)</p><p>Chilblain LE is distinct from lupus pernio, a subtype of sarcoidosis. (See  <a class="medical medical_review" href="/z/d/html/13762.html" rel="external">"Cutaneous manifestations of sarcoidosis", section on 'Lupus pernio'</a>.)</p><p class="headingAnchor" id="H107130746"><span class="h4">Lupus erythematosus-lichen planus overlap syndrome</span><span class="headingEndMark"> — </span>LE-LP overlap syndrome is a rare, chronic disorder that has clinical, histopathologic, and immunofluorescence findings of both LE and lichen planus [<a href="#rid63">63,64</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical manifestations </strong>– The cutaneous findings of LE-LP overlap syndrome are usually persistent atrophic blue-red to violaceous plaques or patches. The most common sites for involvement are the acral portions of the extremities, particularly the palms and soles. The nails are commonly involved, and there may be anonychia (absence of the nail). Photosensitivity and pruritus are generally absent.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Histopathology </strong>–<strong> </strong>Histopathologic examination may reveal features of lichen planus (hyperkeratosis, hypergranulosis, irregular acanthosis, pigment incontinence) and LE. Similarly, direct immunofluorescence (DIF) microscopy may reveal features of lichen planus (cytoid bodies staining for IgM and fibrin in a fibrillar pattern) and LE (immunoglobulin and complement deposition in a linear granular pattern along the dermal-epidermal junction) [<a href="#rid65">65</a>]. (See  <a class="medical medical_review" href="/z/d/html/5662.html" rel="external">"Lichen planus"</a>.)</p><p></p><p class="headingAnchor" id="H538170103"><span class="h2">Diagnosis</span><span class="headingEndMark"> — </span>In general, cutaneous LE is largely a clinical diagnosis supported by contextual clinical features (such as the presence of known underlying SLE). Confirmatory histopathologic examination is indicated when diagnostic uncertainty remains (eg, atypical clinical presentation or clinical features that overlap with other cutaneous diseases). For example, localized ACLE often can be diagnosed by recognition of erythema in the classic malar distribution in a patient with known SLE, and clinical recognition of an eruption with the classic morphology and distribution of DLE is acceptable for the diagnosis of DLE. In contrast, the skin lesions of lupus profundus are often biopsied because of the nonspecific appearance of cutaneous nodules, and tumid lupus erythematosus is often biopsied because of the nonspecific clinical features and absence of an association with SLE. The overlap in the appearance of SCLE with other papulosquamous or annular skin disorders often warrants a biopsy; however, in a patient who also exhibits photosensitivity and positive SSA/Ro antibodies, diagnosis without a biopsy is reasonable.</p><p>Performance of direct immunofluorescence is of variable utility if the diagnosis remains uncertain after clinical and histologic evaluation. (See <a class="local">'Direct immunofluorescence (lupus band test)'</a> below.)</p><p>Other than the strong association between Ro/SSA antibodies for SCLE, there are no antibodies that are routinely predictive of variants of CLE. (See <a class="local">'Subacute cutaneous lupus erythematosus'</a> above.)</p><p>Given the association of cutaneous LE with SLE, patients with cutaneous LE should be evaluated for SLE. While no clear guidelines exist for SLE screening or monitoring of the patient first presenting with cutaneous LE, obtaining a clinical history with a particular focus on a rheumatologic review of systems is recommended. A physical examination and select laboratory studies also should be performed. The evaluation for SLE is reviewed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/4668.html" rel="external">"Clinical manifestations and diagnosis of systemic lupus erythematosus in adults"</a> and  <a class="medical medical_review" href="/z/d/html/6420.html" rel="external">"Childhood-onset systemic lupus erythematosus (SLE): Clinical manifestations and diagnosis"</a>.)</p><p>If systemic features of SLE or laboratory abnormalities are present, referral to a rheumatologist is appropriate for further evaluation and comanagement.</p><p class="headingAnchor" id="H538170199"><span class="h3">Direct immunofluorescence (lupus band test)</span><span class="headingEndMark"> — </span>Direct immunofluorescence (DIF) evaluation of lesional or nonlesional skin for deposition of a continuous band of immunoreactants along the dermal-epidermal junction as part of the evaluation for cutaneous lupus or SLE is historically referred to as the "<strong>lupus band test</strong>." Use of the terms "lesional lupus band test" and "nonlesional lupus band test" can help to clarify the source of the tissue used for the test. Overall, DIF is of unclear value for the diagnosis of cutaneous LE. Therefore, we do not routinely perform DIF.</p><p>Occasionally, demonstration of a continuous band of immunoreactants at the dermal-epidermal junction in tissue taken from a site of cutaneous LE (ie, lesional lupus band test) is used to support a diagnosis of cutaneous LE when histologic findings are nondiagnostic  (<a class="graphic graphic_picture graphicRef91565" href="/z/d/graphic/91565.html" rel="external">picture 14</a>) [<a href="#rid66">66,67</a>]. Although these findings are detected in lesional skin from most patients with ACLE, the finding is not pathognomonic [<a href="#rid68">68,69</a>]. In particular, biopsies from sun-exposed skin from individuals without cutaneous LE or SLE have demonstrated similar features, as shown in a prospective study of 50 healthy young adults that found deposition of immunoglobulins at the dermal-epidermal junction in 10 of 50 biopsy specimens (20 percent) taken from sun-exposed skin [<a href="#rid69">69</a>]. A subsequent study that did not find immunoreactant deposition in sun-exposed skin from 41 healthy adults may have yielded different results because of differences in protocol or other factors [<a href="#rid70">70</a>].</p><p class="headingAnchor" id="H538182076"><span class="h2">Management</span><span class="headingEndMark"> — </span>The approach to the treatment of LE-specific skin disease is influenced by the subtype of disease and the presence of underlying SLE. In all cases, photoprotection and use of appropriate broad-spectrum sunscreens are recommended, given the known photoexacerbation of cutaneous LE. Patients should also be monitored for the development of signs or symptoms suggestive of progression to SLE. (See  <a class="medical medical_review" href="/z/d/html/13751.html" rel="external">"Selection of sunscreen and sun-protective measures"</a> and  <a class="medical medical_review" href="/z/d/html/13772.html" rel="external">"Initial management of discoid lupus erythematosus and subacute cutaneous lupus erythematosus", section on 'Photoprotection'</a> and  <a class="medical medical_review" href="/z/d/html/4675.html" rel="external">"Overview of the management and prognosis of systemic lupus erythematosus in adults", section on 'Monitoring response to therapy'</a>.)</p><p>Topical and intralesional corticosteroids, oral glucocorticoids, oral antimalarial drugs, and glucocorticoid-sparing immunomodulatory agents have all been utilized depending on extent of disease and response to first- and second-line therapies. The general approach to management of cutaneous LE is as follows:</p><p>First-line therapy typically involves:</p><p class="bulletIndent1"><span class="glyph">●</span>Photoprotection.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Use of topical or intralesional corticosteroids, topical calcineurin inhibitors, and/or systemic glucocorticoids depending on the extent of involvement and subset of disease.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Systemic antimalarial agents (treatment with either <a class="drug drug_general" data-topicid="8541" href="/z/d/drug information/8541.html" rel="external">hydroxychloroquine</a> or <a class="drug drug_general" data-topicid="9247" href="/z/d/drug information/9247.html" rel="external">chloroquine</a>, or with the addition of quinacrine to either of these agents) [<a href="#rid71">71</a>].</p><p></p><p class="bulletIndent1">Patients who do not initially respond to <a class="drug drug_general" data-topicid="8541" href="/z/d/drug information/8541.html" rel="external">hydroxychloroquine</a> may benefit from transitioning to <a class="drug drug_general" data-topicid="9247" href="/z/d/drug information/9247.html" rel="external">chloroquine</a>, and patients who do not tolerate hydroxychloroquine may tolerate chloroquine [<a href="#rid72">72</a>]. Limited data suggest that treating to a therapeutic hydroxychloroquine blood level may be beneficial in managing cutaneous lupus [<a href="#rid73">73,74</a>].</p><p></p><p>Second-line therapy typically involves glucocorticoid-sparing and immunomodulatory therapy and should take into account underlying SLE end-organ manifestations, if present:</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">Methotrexate</a> (oral or subcutaneous) – Additional benefits may include treatment of SLE with inflammatory arthritis component.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">Mycophenolate</a> mofetil – May be of dual benefit to patients with underlying lupus nephritis, interstitial lung disease variants.</p><p></p><p>Other second- or third-line agents may include:</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="10095" href="/z/d/drug information/10095.html" rel="external">Thalidomide</a>, <a class="drug drug_general" data-topicid="9822" href="/z/d/drug information/9822.html" rel="external">lenalidomide</a>, <a class="drug drug_general" data-topicid="16479" href="/z/d/drug information/16479.html" rel="external">belimumab</a>, systemic retinoids, oral <a class="drug drug_general" data-topicid="9324" href="/z/d/drug information/9324.html" rel="external">dapsone</a> (particularly for bullous lupus), intravenous immunoglobulin (<a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">IVIG</a>), or <a class="drug drug_general" data-topicid="9026" href="/z/d/drug information/9026.html" rel="external">azathioprine</a></p><p></p><p>Limited data suggest benefit of additional therapies, such as <a class="drug drug_general" data-topicid="9514" href="/z/d/drug information/9514.html" rel="external">ustekinumab</a> [<a href="#rid75">75-77</a>], <a class="drug drug_general" data-topicid="94524" href="/z/d/drug information/94524.html" rel="external">apremilast</a> [<a href="#rid78">78</a>], <a class="drug drug_general" data-topicid="107872" href="/z/d/drug information/107872.html" rel="external">clofazimine</a>, Janus kinase (JAK) inhibitors [<a href="#rid79">79,80</a>], <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">cyclophosphamide</a>, and other interventions. In addition, the findings of a prospective uncontrolled study and retrospective study suggest that <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a> may be useful for some patients with refractory cutaneous LE [<a href="#rid81">81,82</a>].</p><p>The treatment of DLE and SCLE is discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/13772.html" rel="external">"Initial management of discoid lupus erythematosus and subacute cutaneous lupus erythematosus", section on 'Photoprotection'</a> and  <a class="medical medical_review" href="/z/d/html/13775.html" rel="external">"Management of discoid lupus erythematosus and subacute cutaneous lupus erythematosus refractory to antimalarial therapy"</a>.)</p><p class="headingAnchor" id="H127907035"><span class="h1">LUPUS NONSPECIFIC SKIN DISEASE</span><span class="headingEndMark"> — </span>Cutaneous disorders that occur with increased frequency among patients with systemic lupus erythematosus (SLE), but are not specific to SLE and lack histopathologic features of cutaneous LE comprise LE-nonspecific skin disease  (<a class="graphic graphic_table graphicRef93814" href="/z/d/graphic/93814.html" rel="external">table 4</a>). Of note, many of these lupus nonspecific skin diseases are reported to occur with flares of underlying SLE.</p><p class="headingAnchor" id="H107133672"><span class="h2">Vascular abnormalities</span><span class="headingEndMark"> — </span>Examples of cutaneous manifestations of vascular involvement in SLE include periungual erythema, livedo reticularis, telangiectasia, Raynaud phenomenon, and vasculitis. Cutaneous vascular abnormalities occur in approximately 50 percent of patients with SLE [<a href="#rid83">83</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Periungual erythema </strong>– Periungual erythema is due to dilated tortuous loops of capillaries and a prominent subcapillary venous plexus along the base of the nail. Similar findings have been noted along the edges of the upper eyelid.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Livedo reticularis </strong>– Livedo reticularis refers to a reddish-cyanotic, reticular pattern on the skin of the arms, legs, and torso, particularly with cold exposure  (<a class="graphic graphic_picture graphicRef79545 graphicRef61842" href="/z/d/graphic/79545.html" rel="external">picture 15A-B</a>). In SLE, livedo reticularis is induced by vasospasm of the dermal ascending arterioles [<a href="#rid84">84</a>]. Vasospasm in these cutaneous vessels results in decreased blood supply to the superficial horizontal vascular plexus, with a secondary increase in circulation to the remaining patent vessels. Pathologic examination of involved blood vessels reveals thickening of the walls of the dermal vessels with subsequent narrowing of the lumens and, in some cases, intravascular thrombi.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Raynaud phenomenon </strong>– Raynaud phenomenon in SLE is a vasospastic process that occurs in approximately 15 to 30 percent of patients [<a href="#rid85">85</a>]. It is characterized by blanching of the nail beds, fingers, and toes (and occasionally ears, nose, tongue, and nipples) with accompanying pain. Involvement of the thumb or severe disease that leads to distal digital ulceration should raise suspicion for features of overlap with systemic sclerosis. Chilblains (perniosis) may occur concurrently with Raynaud phenomenon and may have distinct treatment considerations. (See  <a class="medical medical_review" href="/z/d/html/7543.html" rel="external">"Clinical manifestations and diagnosis of Raynaud phenomenon"</a> and  <a class="medical medical_review" href="/z/d/html/13758.html" rel="external">"Pernio (chilblains)"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Vasculitis </strong>– Vasculitis develops in approximately 11 to 20 percent of patients with SLE [<a href="#rid83">83,84,86</a>]. The most common form, occurring in 10 to 15 percent of cases, is urticarial vasculitis. In contrast to urticaria, lesions of urticarial vasculitis may persist for more than 24 hours and frequently evolve into painful petechiae or purpura that may heal with hyperpigmentation. (See  <a class="medical medical_review" href="/z/d/html/8218.html" rel="external">"Urticarial vasculitis"</a>.)</p><p></p><p class="bulletIndent1">Vasculitis may also affect small arteries, possibly resulting in microinfarcts of the tips of the fingers, the toes, the cuticles of the nail folds (splinter hemorrhages), and the extensor surface of the forearm and shin  (<a class="graphic graphic_picture graphicRef67922" href="/z/d/graphic/67922.html" rel="external">picture 16</a>). The palms of the hand, soles of the feet, and area around the ankle are less commonly involved [<a href="#rid87">87</a>]. Ankle involvement may develop into painful punched-out ulcers and may heal slowly. Periarteritis nodosa-like lesions may occur.</p><p></p><p class="headingAnchor" id="H538172748"><span class="h2">Nonscarring alopecia</span><span class="headingEndMark"> — </span>Nonscarring (reversible) hair loss in patients with SLE may reflect telogen effluvium or "lupus hair." Nonscarring hair loss usually responds well to treatment of SLE.</p><p>Telogen effluvium is characterized by a shift in follicular cycling that leads to premature shedding of hair. Telogen effluvium can occur in the setting of serious illness or other significant physiologic stressors. (See  <a class="medical medical_review" href="/z/d/html/15683.html" rel="external">"Telogen effluvium"</a>.)</p><p>"Lupus hair" is generally seen during exacerbations of SLE. It is characterized by thin, unruly hair that easily fractures [<a href="#rid88">88</a>]. Lupus hair usually occurs along the frontal hairline.</p><p class="headingAnchor" id="H203917022"><span class="h2">Other</span><span class="headingEndMark"> — </span>Nail abnormalities, particularly pitting, ridging, and onycholysis, have been noted in 25 percent of patients with SLE [<a href="#rid89">89</a>]. Approximately 20 percent of patients have redness of the lunula, a finding nearly always associated with periungual erythema [<a href="#rid90">90</a>].</p><p>Papulonodular mucinosis is another LE-nonspecific skin disorder. This disorder typically presents as asymptomatic, skin-colored papules or nodules on the trunk or proximal extremities and abundant mucin in the papillary dermis and mid-dermis [<a href="#rid91">91</a>].</p><p>Multiple disseminated eruptive dermatofibromas have been reported in SLE, especially in immunosuppressed patients [<a href="#rid92">92</a>].</p><p>Additional disorders included among LE-nonspecific skin disorders include [<a href="#rid1">1</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Sclerodactyly</p><p class="bulletIndent1"><span class="glyph">●</span>Rheumatoid nodules</p><p class="bulletIndent1"><span class="glyph">●</span>Calcinosis cutis</p><p class="bulletIndent1"><span class="glyph">●</span>Nonspecific bullous eruptions (resulting from damage to the basal layer of the epidermis)</p><p class="bulletIndent1"><span class="glyph">●</span>Urticaria</p><p class="bulletIndent1"><span class="glyph">●</span>Cutis laxa/anetoderma</p><p class="bulletIndent1"><span class="glyph">●</span>Acanthosis nigricans</p><p class="bulletIndent1"><span class="glyph">●</span>Erythema multiforme</p><p class="bulletIndent1"><span class="glyph">●</span>Leg ulcers</p><p class="bulletIndent1"><span class="glyph">●</span>Palisaded neutrophilic and granulomatous dermatitis</p><p></p><p class="headingAnchor" id="H538180595"><span class="h1">OTHER MANIFESTATIONS</span></p><p class="headingAnchor" id="H203916837"><span class="h2">Mucosal manifestations</span><span class="headingEndMark"> — </span>Mucous membrane involvement can occur in the setting of cutaneous LE or systemic lupus erythematosus (SLE). Mucosal involvement occurs in 12 to 45 percent of patients with SLE [<a href="#rid93">93-95</a>]. </p><p>Oral involvement may manifest as white plaques, areas of erythema, or punched-out erosions or ulcers with surrounding erythema on the soft or hard palate or buccal mucosa  (<a class="graphic graphic_picture graphicRef63605" href="/z/d/graphic/63605.html" rel="external">picture 17</a>). The oral ulcers are usually painless. Oral ulcers may be the first sign of SLE. There is no apparent association between the presence of oral ulcers and systemic activity.</p><p>The oral manifestations of LE may demonstrate the typical histopathology of discoid lupus erythematosus (DLE), including hyperkeratosis, atrophy of rete processes, and superficial and deep inflammatory infiltrates; edema in the lamina propria, continuous or patchy periodic acid-Schiff (PAS)-positive deposits in the basement membrane zone, deposition of intercellular mucin, and deposits of immunoglobulin and complement at the dermal-epidermal junction are also seen [<a href="#rid95">95,96</a>]. Oral LE should be distinguished from lichen planus, candidiasis, aphthous stomatitis, intraoral herpes, Behçet syndrome, bite marks, leukoplakia, and malignancy.</p><p>Nasal ulcers occur in some patients with SLE [<a href="#rid97">97</a>]. They are usually in the lower nasal septum and tend to be bilateral. The appearance of nasal ulcers tends to parallel other features of active SLE. Nasal perforation, possibly secondary to vasculitis, is infrequent, occurring in 4.6 percent of 885 patients with SLE who were prospectively followed [<a href="#rid98">98</a>]. Involvement of the mucosa of the upper airway may also occur and may cause hoarseness [<a href="#rid87">87</a>].</p><p>Oral mucous membrane lesions may respond to topical corticosteroids, <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">tacrolimus</a> 0.1% ointment, intralesional corticosteroids, and systemic antimalarial drugs. The response to topical corticosteroids (usually Orabase mixed with either <a class="drug drug_general" data-topicid="10015" href="/z/d/drug information/10015.html" rel="external">triamcinolone</a> 0.1% or <a class="drug drug_general" data-topicid="9276" href="/z/d/drug information/9276.html" rel="external">clobetasol</a> 0.05%) takes a few days to weeks, while the response to <a class="drug drug_general" data-topicid="8541" href="/z/d/drug information/8541.html" rel="external">hydroxychloroquine</a> takes weeks to months. If the oral LE is refractory to these interventions and is causing significant symptoms, more aggressive systemic therapies used for cutaneous LE may be tried. (See  <a class="medical medical_review" href="/z/d/html/13775.html" rel="external">"Management of discoid lupus erythematosus and subacute cutaneous lupus erythematosus refractory to antimalarial therapy"</a>.)</p><p class="headingAnchor" id="H538180729"><span class="h2">Bullous cutaneous lupus erythematosus</span><span class="headingEndMark"> — </span>Bullous cutaneous lupus erythematosus (bullous CLE) is a rare and distinct complication of SLE characterized by the development of autoantibodies against type VII collagen and subepidermal blistering [<a href="#rid99">99,100</a>]. Affected patients develop a vesicular or bullous eruption that may affect any body site, including oral mucosa  (<a class="graphic graphic_picture graphicRef66048" href="/z/d/graphic/66048.html" rel="external">picture 18A</a>). There is a predilection for the upper trunk, upper extremities, and neck. Bullae may arise on normal or erythematous skin. Pruritus is usually absent. Dyspigmentation may occur in sites of resolved bullae. Scarring usually does not occur.</p><p>Typical biopsy findings in bullous CLE include subepidermal blistering and a neutrophil-predominant infiltrate in the upper dermis and dermal edema  (<a class="graphic graphic_picture graphicRef66048 graphicRef86217" href="/z/d/graphic/66048.html" rel="external">picture 18A-B</a>). Vasculitis may be present. Direct immunofluorescence studies demonstrate deposition of immunoglobulin (Ig)G, IgA, IgM, and/or complement at the basement membrane zone [<a href="#rid99">99</a>].</p><p>Oral <a class="drug drug_general" data-topicid="9324" href="/z/d/drug information/9324.html" rel="external">dapsone</a> is the mainstay of treatment. Responses to dapsone are often rapid.</p><p class="headingAnchor" id="H538173659"><span class="h2">Neonatal lupus</span><span class="headingEndMark"> — </span>Neonatal lupus is a rare syndrome that is associated with maternal antibodies to Ro/SSA, to La/SSB, and, much less frequently, to U1RNP. Infants develop eruptions characterized by erythematous arcuate patches or plaques with raised active margins shortly after birth  (<a class="graphic graphic_picture graphicRef51166" href="/z/d/graphic/51166.html" rel="external">picture 6</a>). Congenital heart block is the most concerning complication of neonatal lupus. Following the birth of an infant with neonatal lupus, the risk for congenital heart block is increased with subsequent pregnancies [<a href="#rid101">101</a>]. Of note, treatment with <a class="drug drug_general" data-topicid="8541" href="/z/d/drug information/8541.html" rel="external">hydroxychloroquine</a> may decrease the risk of neonatal lupus (congenital heart block) in at-risk pregnancies [<a href="#rid102">102</a>]. Neonatal lupus erythematosus is reviewed separately. (See  <a class="medical medical_review" href="/z/d/html/6402.html" rel="external">"Neonatal lupus: Epidemiology, pathogenesis, clinical manifestations, and diagnosis"</a>.)</p><p class="headingAnchor" id="H1306202838"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/119580.html" rel="external">"Society guideline links: Cutaneous lupus erythematosus"</a>.)</p><p class="headingAnchor" id="H437961199"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topic (see  <a class="medical medical_basics" href="/z/d/html/87700.html" rel="external">"Patient education: Discoid lupus (The Basics)"</a>)</p><p></p><p class="headingAnchor" id="H14812788"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Classification</strong> – Cutaneous lupus erythematosus (cutaneous LE) may occur as an independent disorder or in association with systemic lupus erythematosus (SLE). Cutaneous LE includes three categories of LE-specific skin disease: acute cutaneous lupus erythematosus (ACLE), subacute cutaneous lupus erythematosus (SCLE), and chronic cutaneous lupus erythematosus (CCLE). A variety of non-LE cutaneous disorders may also occur in patients with SLE (LE-nonspecific skin diseases). (See <a class="local">'Classification'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Association with systemic lupus erythematosus</strong> – The different types of LE-specific skin disease have varying strengths of association with SLE  (<a class="graphic graphic_figure graphicRef109668" href="/z/d/graphic/109668.html" rel="external">figure 1</a>). Whereas ACLE almost always occurs in association with SLE, other types of lupus-specific skin disease are less strongly associated with SLE. (See <a class="local">'Association with systemic lupus erythematosus'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Acute cutaneous lupus erythematosus</strong> – ACLE may occur as a localized, generalized, or toxic epidermal necrolysis-like eruption. The most common manifestation is the localized facial eruption (malar rash, butterfly rash), which is characterized by the development of erythema over the cheeks and bridge of the nose  (<a class="graphic graphic_picture graphicRef75781 graphicRef55875" href="/z/d/graphic/75781.html" rel="external">picture 1A-B</a>). ACLE may last for hours, days, or weeks and often recurs. (See <a class="local">'Acute cutaneous lupus erythematosus'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Subacute cutaneous lupus erythematosus</strong> – SCLE may occur as an idiopathic eruption, in association with SLE, or as a drug-induced disorder. SCLE classically presents as psoriasiform or annular erythematous plaques on the shoulders, forearms, neck, or upper torso  (<a class="graphic graphic_picture graphicRef55903 graphicRef66580" href="/z/d/graphic/55903.html" rel="external">picture 4A-B</a>). There is a strong association with Ro/SSA autoantibodies. The possibility of drug-induced SCLE should always be reviewed, particularly when skin involvement is widespread or severe. (See <a class="local">'Subacute cutaneous lupus erythematosus'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Discoid lupus erythematosus</strong> – Discoid lupus erythematosus (DLE) is the most common form of CCLE. Patients with DLE develop erythematous, scaly plaques that may exhibit follicular plugging and heal with scarring  (<a class="graphic graphic_picture graphicRef75833 graphicRef64844 graphicRef72588 graphicRef53535" href="/z/d/graphic/75833.html" rel="external">picture 7A-D</a>). Associated hypopigmentation and hyperpigmentation are common. Frequent sites for DLE are the face, neck, scalp, and ears. Patients with the generalized variant of DLE also have involvement of the trunk or extremities. A hypertrophic variant of DLE is characterized by hyperkeratotic, verrucous plaques. LE tumidus, lupus profundus, chilblain LE, and lichenoid cutaneous lupus erythematosus-lichen planus overlap syndrome are additional subtypes of CCLE. (See <a class="local">'Chronic cutaneous lupus erythematosus'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis</strong> – Cutaneous LE is largely a clinical diagnosis supported by contextual clinical features (such as the presence of known underlying SLE). Confirmatory histopathologic examination is indicated when diagnostic uncertainty remains. Select patients with known SLE and/or classic clinical features of cutaneous LE may not require a biopsy. (See <a class="local">'Diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management</strong> – The approach to the management of cutaneous LE is influenced by the extent of disease, subtype of cutaneous LE, response to initial therapy, and the presence of underlying SLE. Photoprotection, topical corticosteroids, topical calcineurin inhibitors, and oral antimalarials are common first-line treatments. (See <a class="local">'Management'</a> above.)</p><p></p><p class="headingAnchor" id="H731738598"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Samuel L Moschella, MD, FAAD, FACP, who contributed to an earlier version of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Lee HJ, Sinha AA. Cutaneous lupus erythematosus: understanding of clinical features, genetic basis, and pathobiology of disease guides therapeutic strategies. Autoimmunity 2006; 39:433.</a></li><li><a class="nounderline abstract_t">Biazar C, Sigges J, Patsinakidis N, et al. Cutaneous lupus erythematosus: first multicenter database analysis of 1002 patients from the European Society of Cutaneous Lupus Erythematosus (EUSCLE). Autoimmun Rev 2013; 12:444.</a></li><li><a class="nounderline abstract_t">Watanabe T, Tsuchida T. Classification of lupus erythematosus based upon cutaneous manifestations. Dermatological, systemic and laboratory findings in 191 patients. Dermatology 1995; 190:277.</a></li><li><a class="nounderline abstract_t">Klein RS, Morganroth PA, Werth VP. Cutaneous lupus and the Cutaneous Lupus Erythematosus Disease Area and Severity Index instrument. Rheum Dis Clin North Am 2010; 36:33.</a></li><li><a class="nounderline abstract_t">Vera-Recabarren MA, García-Carrasco M, Ramos-Casals M, Herrero C. Comparative analysis of subacute cutaneous lupus erythematosus and chronic cutaneous lupus erythematosus: clinical and immunological study of 270 patients. Br J Dermatol 2010; 162:91.</a></li><li><a class="nounderline abstract_t">Jarukitsopa S, Hoganson DD, Crowson CS, et al. Epidemiology of systemic lupus erythematosus and cutaneous lupus erythematosus in a predominantly white population in the United States. Arthritis Care Res (Hoboken) 2015; 67:817.</a></li><li><a class="nounderline abstract_t">Durosaro O, Davis MD, Reed KB, Rohlinger AL. Incidence of cutaneous lupus erythematosus, 1965-2005: a population-based study. Arch Dermatol 2009; 145:249.</a></li><li><a class="nounderline abstract_t">Grönhagen CM, Fored CM, Granath F, Nyberg F. Cutaneous lupus erythematosus and the association with systemic lupus erythematosus: a population-based cohort of 1088 patients in Sweden. Br J Dermatol 2011; 164:1335.</a></li><li><a class="nounderline abstract_t">Sontheimer RD. Subacute cutaneous lupus erythematosus: 25-year evolution of a prototypic subset (subphenotype) of lupus erythematosus defined by characteristic cutaneous, pathological, immunological, and genetic findings. Autoimmun Rev 2005; 4:253.</a></li><li><a class="nounderline abstract_t">Chong BF, Song J, Olsen NJ. Determining risk factors for developing systemic lupus erythematosus in patients with discoid lupus erythematosus. Br J Dermatol 2012; 166:29.</a></li><li><a class="nounderline abstract_t">Watanabe T, Tsuchida T. Lupus erythematosus profundus: a cutaneous marker for a distinct clinical subset? Br J Dermatol 1996; 134:123.</a></li><li><a class="nounderline abstract_t">Maize JC Jr, Costner M. Tumid lupus erythematosus: a form of lupus erythematosus. Arch Dermatol 2010; 146:451; author reply 450.</a></li><li><a class="nounderline abstract_t">Petersen MP, Möller S, Bygum A, et al. Epidemiology of cutaneous lupus erythematosus and the associated risk of systemic lupus erythematosus: a nationwide cohort study in Denmark. Lupus 2018; 27:1424.</a></li><li><a class="nounderline abstract_t">Monga B, Ghosh S, Jain V. Toxic Epidermal Necrolysis-like Rash of Lupus: A Dermatologist's Dilemma. Indian J Dermatol 2014; 59:401.</a></li><li><a class="nounderline abstract_t">Yildirim Cetin G, Sayar H, Ozkan F, et al. A case of toxic epidermal necrolysis-like skin lesions with systemic lupus erythematosus and review of the literature. Lupus 2013; 22:839.</a></li><li><a class="nounderline abstract_t">Napolitano M, Giampetruzzi AR, Didona D, et al. Toxic epidermal necrolysis-like acute cutaneous lupus erythematosus successfully treated with a single dose of etanercept: report of three cases. J Am Acad Dermatol 2013; 69:e303.</a></li><li><a class="nounderline abstract_t">Ting W, Stone MS, Racila D, et al. Toxic epidermal necrolysis-like acute cutaneous lupus erythematosus and the spectrum of the acute syndrome of apoptotic pan-epidermolysis (ASAP): a case report, concept review and proposal for new classification of lupus erythematosus vesiculobullous skin lesions. Lupus 2004; 13:941.</a></li><li><a class="nounderline abstract_t">Paradela S, Martínez-Gómez W, Fernández-Jorge B, et al. Toxic epidermal necrolysis-like acute cutaneous lupus erythematosus. Lupus 2007; 16:741.</a></li><li><a class="nounderline abstract_t">Mandelcorn R, Shear NH. Lupus-associated toxic epidermal necrolysis: a novel manifestation of lupus? J Am Acad Dermatol 2003; 48:525.</a></li><li><a class="nounderline abstract_t">Sepehr A, Wenson S, Tahan SR. Histopathologic manifestations of systemic diseases: the example of cutaneous lupus erythematosus. J Cutan Pathol 2010; 37 Suppl 1:112.</a></li><li><a class="nounderline abstract_t">Black AA, McCauliffe DP, Sontheimer RD. Prevalence of acne rosacea in a rheumatic skin disease subspecialty clinic. Lupus 1992; 1:229.</a></li><li><a class="nounderline abstract_t">Sontheimer RD, Thomas JR, Gilliam JN. Subacute cutaneous lupus erythematosus: a cutaneous marker for a distinct lupus erythematosus subset. Arch Dermatol 1979; 115:1409.</a></li><li><a class="nounderline abstract_t">Stavropoulos PG, Goules AV, Avgerinou G, Katsambas AD. Pathogenesis of subacute cutaneous lupus erythematosus. J Eur Acad Dermatol Venereol 2008; 22:1281.</a></li><li><a class="nounderline abstract_t">Fabbri P, Cardinali C, Giomi B, Caproni M. Cutaneous lupus erythematosus: diagnosis and management. Am J Clin Dermatol 2003; 4:449.</a></li><li><a class="nounderline abstract_t">Werth VP, Zhang W, Dortzbach K, Sullivan K. Association of a promoter polymorphism of tumor necrosis factor-alpha with subacute cutaneous lupus erythematosus and distinct photoregulation of transcription. J Invest Dermatol 2000; 115:726.</a></li><li><a class="nounderline abstract_t">Lin JH, Dutz JP, Sontheimer RD, Werth VP. Pathophysiology of cutaneous lupus erythematosus. Clin Rev Allergy Immunol 2007; 33:85.</a></li><li><a class="nounderline abstract_t">Marzano AV, Lazzari R, Polloni I, et al. Drug-induced subacute cutaneous lupus erythematosus: evidence for differences from its idiopathic counterpart. Br J Dermatol 2011; 165:335.</a></li><li><a class="nounderline abstract_t">Callen JP, Hodge SJ, Kulick KB, et al. Subacute cutaneous lupus erythematosus in multiple members of a family with C2 deficiency. Arch Dermatol 1987; 123:66.</a></li><li><a class="nounderline abstract_t">Provost TT, Arnett FC, Reichlin M. Homozygous C2 deficiency, lupus erythematosus, and anti-Ro (SSA) antibodies. Arthritis Rheum 1983; 26:1279.</a></li><li><a class="nounderline abstract_t">Black DR, Hornung CA, Schneider PD, Callen JP. Frequency and severity of systemic disease in patients with subacute cutaneous lupus erythematosus. Arch Dermatol 2002; 138:1175.</a></li><li><a class="nounderline abstract_t">Patel P, Werth V. Cutaneous lupus erythematosus: a review. Dermatol Clin 2002; 20:373.</a></li><li><a class="nounderline abstract_t">Ziemer M, Milkova L, Kunz M. Lupus erythematosus. Part II: clinical picture, diagnosis and treatment. J Dtsch Dermatol Ges 2014; 12:285.</a></li><li><a class="nounderline abstract_t">Grönhagen CM, Fored CM, Linder M, et al. Subacute cutaneous lupus erythematosus and its association with drugs: a population-based matched case-control study of 234 patients in Sweden. Br J Dermatol 2012; 167:296.</a></li><li><a class="nounderline abstract_t">Srivastava M, Rencic A, Diglio G, et al. Drug-induced, Ro/SSA-positive cutaneous lupus erythematosus. Arch Dermatol 2003; 139:45.</a></li><li><a class="nounderline abstract_t">Callen JP, Hughes AP, Kulp-Shorten C. Subacute cutaneous lupus erythematosus induced or exacerbated by terbinafine: a report of 5 cases. Arch Dermatol 2001; 137:1196.</a></li><li><a class="nounderline abstract_t">Sontheimer RD, Henderson CL, Grau RH. Drug-induced subacute cutaneous lupus erythematosus: a paradigm for bedside-to-bench patient-oriented translational clinical investigation. Arch Dermatol Res 2009; 301:65.</a></li><li><a class="nounderline abstract_t">Guicciardi F, Atzori L, Marzano AV, et al. Are there distinct clinical and pathological features distinguishing idiopathic from drug-induced subacute cutaneous lupus erythematosus? A European retrospective multicenter study. J Am Acad Dermatol 2019; 81:403.</a></li><li><a class="nounderline abstract_t">Hillesheim PB, Bahrami S, Jeffy BG, Callen JP. Tissue eosinophilia: not an indicator of drug-induced subacute cutaneous lupus erythematosus. Arch Dermatol 2012; 148:190.</a></li><li><a class="nounderline abstract_t">Cardinali C, Caproni M, Bernacchi E, et al. The spectrum of cutaneous manifestations in lupus erythematosus--the Italian experience. Lupus 2000; 9:417.</a></li><li><a class="nounderline abstract_t">Gilliam JN, Sontheimer RD. Distinctive cutaneous subsets in the spectrum of lupus erythematosus. J Am Acad Dermatol 1981; 4:471.</a></li><li><a class="nounderline abstract_t">Wallace DJ, Pistiner M, Nessim S, et al. Cutaneous lupus erythematosus without systemic lupus erythematosus: clinical and laboratory features. Semin Arthritis Rheum 1992; 21:221.</a></li><li><a class="nounderline abstract_t">Merola JF, Prystowsky SD, Iversen C, et al. Association of discoid lupus erythematosus with other clinical manifestations among patients with systemic lupus erythematosus. J Am Acad Dermatol 2013; 69:19.</a></li><li><a class="nounderline abstract_t">Pons-Estel GJ, Aspey LD, Bao G, et al. Early discoid lupus erythematosus protects against renal disease in patients with systemic lupus erythematosus: longitudinal data from a large Latin American cohort. Lupus 2017; 26:73.</a></li><li><a class="nounderline abstract_t">Wieczorek IT, Propert KJ, Okawa J, Werth VP. Systemic symptoms in the progression of cutaneous to systemic lupus erythematosus. JAMA Dermatol 2014; 150:291.</a></li><li><a class="nounderline abstract_t">Rowell NR. Laboratory abnormalities in the diagnosis and management of lupus erythematosus. Br J Dermatol 1971; 84:210.</a></li><li><a class="nounderline abstract_t">Callen JP. Systemic lupus erythematosus in patients with chronic cutaneous (discoid) lupus erythematosus. Clinical and laboratory findings in seventeen patients. J Am Acad Dermatol 1985; 12:278.</a></li><li><a class="nounderline abstract_t">Elman SA, Joyce C, Costenbader KH, Merola JF. Time to progression from discoid lupus erythematosus to systemic lupus erythematosus: a retrospective cohort study. Clin Exp Dermatol 2020; 45:89.</a></li><li><a class="nounderline abstract_t">Vasquez R, Tseng LC, Victor S, et al. Autoantibody and clinical profiles in patients with discoid lupus and borderline systemic lupus. Arch Dermatol 2012; 148:651.</a></li><li><a class="nounderline abstract_t">Elman SA, Joyce C, Braudis K, et al. Creation and Validation of Classification Criteria for Discoid Lupus Erythematosus. JAMA Dermatol 2020; 156:901.</a></li><li><a class="nounderline abstract_t">Farley-Loftus R, Elmariah SB, Ralston J, et al. Hypertrophic discoid lupus erythematosus. Dermatol Online J 2010; 16:1.</a></li><li><a class="nounderline abstract_t">Zaalberg A, Moradi Tuchayi S, Ameri AH, et al. Chronic Inflammation Promotes Skin Carcinogenesis in Cancer-Prone Discoid Lupus Erythematosus. J Invest Dermatol 2019; 139:62.</a></li><li><a class="nounderline abstract_t">Kuhn A, Richter-Hintz D, Oslislo C, et al. Lupus erythematosus tumidus--a neglected subset of cutaneous Lupus erythematosus: report of 40 cases. Arch Dermatol 2000; 136:1033.</a></li><li><a class="nounderline abstract_t">Böckle BC, Sepp NT. Smoking is highly associated with discoid lupus erythematosus and lupus erythematosus tumidus: analysis of 405 patients. Lupus 2015; 24:669.</a></li><li><a class="nounderline abstract_t">Alexiades-Armenakas MR, Baldassano M, Bince B, et al. Tumid lupus erythematosus: criteria for classification with immunohistochemical analysis. Arthritis Rheum 2003; 49:494.</a></li><li><a class="nounderline abstract_t">Schmitt V, Meuth AM, Amler S, et al. Lupus erythematosus tumidus is a separate subtype of cutaneous lupus erythematosus. Br J Dermatol 2010; 162:64.</a></li><li><a class="nounderline abstract_t">Martens PB, Moder KG, Ahmed I. Lupus panniculitis: clinical perspectives from a case series. J Rheumatol 1999; 26:68.</a></li><li><a class="nounderline abstract_t">Peters MS, Su WP. Lupus erythematosus panniculitis. Med Clin North Am 1989; 73:1113.</a></li><li><a class="nounderline abstract_t">Warne RR, Taylor D, Segal A, Irish A. Lupus mastitis: a mimicker of breast carcinoma. BMJ Case Rep 2011; 2011.</a></li><li><a class="nounderline abstract_t">Crowson AN, Magro C. The cutaneous pathology of lupus erythematosus: a review. J Cutan Pathol 2001; 28:1.</a></li><li><a class="nounderline abstract_t">Parveen Z, Thompson K. Subcutaneous panniculitis-like T-cell lymphoma: redefinition of diagnostic criteria in the recent World Health Organization-European Organization for Research and Treatment of Cancer classification for cutaneous lymphomas. Arch Pathol Lab Med 2009; 133:303.</a></li><li><a class="nounderline abstract_t">Viguier M, Pinquier L, Cavelier-Balloy B, et al. Clinical and histopathologic features and immunologic variables in patients with severe chilblains. A study of the relationship to lupus erythematosus. Medicine (Baltimore) 2001; 80:180.</a></li><li><a class="nounderline abstract_t">Doutre MS, Beylot C, Beylot J, et al. Chilblain lupus erythematosus: report of 15 cases. Dermatology 1992; 184:26.</a></li><li><a class="nounderline abstract_t">Romero RW, Nesbitt LT Jr, Reed RJ. Unusual variant of lupus erythematosus or lichen planus. Clinical, histopathologic, and immunofluorescent studies. Arch Dermatol 1977; 113:741.</a></li><li><a class="nounderline abstract_t">Ahmed AR, Schreiber P, Abramovits W, et al. Coexistence of lichen planus and systemic lupus erythematosus. J Am Acad Dermatol 1982; 7:478.</a></li><li><a class="nounderline abstract_t">Lospinoso DJ, Fernelius C, Edhegard KD, et al. Lupus erythematosus/lichen planus overlap syndrome: successful treatment with acitretin. Lupus 2013; 22:851.</a></li><li><a class="nounderline abstract_t">Mutasim DF, Adams BB. Immunofluorescence in dermatology. J Am Acad Dermatol 2001; 45:803.</a></li><li><a class="nounderline abstract_t">Harrist TJ, Mihm MC Jr. The specificity and clinical usefulness of the lupus band test. Arthritis Rheum 1980; 23:479.</a></li><li><a class="nounderline abstract_t">George R, Kurian S, Jacob M, Thomas K. Diagnostic evaluation of the lupus band test in discoid and systemic lupus erythematosus. Int J Dermatol 1995; 34:170.</a></li><li><a class="nounderline abstract_t">Fabré VC, Lear S, Reichlin M, et al. Twenty percent of biopsy specimens from sun-exposed skin of normal young adults demonstrate positive immunofluorescence. Arch Dermatol 1991; 127:1006.</a></li><li><a class="nounderline abstract_t">Leibold AM, Bennion S, David-Bajar K, Schleve MJ. Occurrence of positive immunofluorescence in the dermo-epidermal junction of sun-exposed skin of normal adults. J Cutan Pathol 1994; 21:200.</a></li><li><a class="nounderline abstract_t">Chasset F, Bouaziz JD, Costedoat-Chalumeau N, et al. Efficacy and comparison of antimalarials in cutaneous lupus erythematosus subtypes: a systematic review and meta-analysis. Br J Dermatol 2017; 177:188.</a></li><li><a class="nounderline abstract_t">Riley K, Schwager Z, Stern M, et al. Assessment of Antimalarial Therapy in Patients Who Are Hypersensitive to Hydroxychloroquine. JAMA Dermatol 2019; 155:491.</a></li><li><a class="nounderline abstract_t">Chasset F, Arnaud L, Costedoat-Chalumeau N, et al. The effect of increasing the dose of hydroxychloroquine (HCQ) in patients with refractory cutaneous lupus erythematosus (CLE): An open-label prospective pilot study. J Am Acad Dermatol 2016; 74:693.</a></li><li><a class="nounderline abstract_t">Francès C, Cosnes A, Duhaut P, et al. Low blood concentration of hydroxychloroquine in patients with refractory cutaneous lupus erythematosus: a French multicenter prospective study. Arch Dermatol 2012; 148:479.</a></li><li><a class="nounderline abstract_t">De Souza A, Ali-Shaw T, Strober BE, Franks AG Jr. Successful treatment of subacute lupus erythematosus with ustekinumab. Arch Dermatol 2011; 147:896.</a></li><li><a class="nounderline abstract_t">Winchester D, Duffin KC, Hansen C. Response to ustekinumab in a patient with both severe psoriasis and hypertrophic cutaneous lupus. Lupus 2012; 21:1007.</a></li><li><a class="nounderline abstract_t">Varada S, Gottlieb AB, Merola JF, et al. Treatment of coexistent psoriasis and lupus erythematosus. J Am Acad Dermatol 2015; 72:253.</a></li><li><a class="nounderline abstract_t">De Souza A, Strober BE, Merola JF, et al. Apremilast for discoid lupus erythematosus: results of a phase 2, open-label, single-arm, pilot study. J Drugs Dermatol 2012; 11:1224.</a></li><li><a class="nounderline abstract_t">Bonnardeaux E, Dutz JP. Oral tofacitinib citrate for recalcitrant cutaneous lupus. JAAD Case Rep 2022; 20:61.</a></li><li><a class="nounderline abstract_t">Wenzel J, van Holt N, Maier J, et al. JAK1/2 Inhibitor Ruxolitinib Controls a Case of Chilblain Lupus Erythematosus. J Invest Dermatol 2016; 136:1281.</a></li><li><a class="nounderline abstract_t">Vital EM, Wittmann M, Edward S, et al. Brief report: responses to rituximab suggest B cell-independent inflammation in cutaneous systemic lupus erythematosus. Arthritis Rheumatol 2015; 67:1586.</a></li><li><a class="nounderline abstract_t">Quelhas da Costa R, Aguirre-Alastuey ME, Isenberg DA, Saracino AM. Assessment of Response to B-Cell Depletion Using Rituximab in Cutaneous Lupus Erythematosus. JAMA Dermatol 2018; 154:1432.</a></li><li class="breakAll">Sontheimer RD, Gilliam JN. Systemic lupus erythematosus and the skin. In: Systemic Lupus Erythematosus, Lahita RG (Ed), Churchill Livingstone, 1992.</li><li class="breakAll">McCauliffe DP, Sontheimer RD. Cutaneous lupus erythematosus. In: The Clinical Management of Systemic Lupus Erythematosus, 2nd ed, Schur PH (Ed), Lippincott, 1996.</li><li><a class="nounderline abstract_t">Kammer GM, Soter NA, Schur PH. Circulating immune complexes in patients with necrotizing vasculitis. Clin Immunol Immunopathol 1980; 15:658.</a></li><li><a class="nounderline abstract_t">Ramos-Casals M, Nardi N, Lagrutta M, et al. Vasculitis in systemic lupus erythematosus: Prevalence and clinical characteristics in 670 patients. Medicine (Baltimore) 2006; 85:95.</a></li><li class="breakAll">Ropes MW. Systemic Lupus Erythematosus, Harvard University Press, 1976.</li><li><a class="nounderline abstract_t">Alarcon-Segovia D, Cetina JA. Lupus hair. Am J Med Sci 1974; 267:241.</a></li><li><a class="nounderline abstract_t">Urowitz MB, Gladman DD, Chalmers A, Ogryzlo MA. Nail lesions in systemic lupus erythematosus. J Rheumatol 1978; 5:441.</a></li><li><a class="nounderline abstract_t">Wollina U, Barta U, Uhlemann C, Oelzner P. Lupus erythematosus-associated red lunula. J Am Acad Dermatol 1999; 41:419.</a></li><li><a class="nounderline abstract_t">Desai S, Korta DZ, Patel RR, Sanchez MR. Papulonodular mucinosis in a patient with systemic lupus erythematosus and antiphospholipid syndrome. J Drugs Dermatol 2014; 13:621.</a></li><li><a class="nounderline abstract_t">Massone C, Parodi A, Virno G, Rebora A. Multiple eruptive dermatofibromas in patients with systemic lupus erythematosus treated with prednisone. Int J Dermatol 2002; 41:279.</a></li><li><a class="nounderline abstract_t">Urman JD, Lowenstein MB, Abeles M, Weinstein A. Oral mucosal ulceration in systemic lupus erythematosus. Arthritis Rheum 1978; 21:58.</a></li><li><a class="nounderline abstract_t">Jonsson R, Heyden G, Westberg NG, Nyberg G. Oral mucosal lesions in systemic lupus erythematosus--a clinical, histopathological and immunopathological study. J Rheumatol 1984; 11:38.</a></li><li><a class="nounderline abstract_t">Lourenço SV, Nacagami Sotto M, Constantino Vilela MA, et al. Lupus erythematosus: clinical and histopathological study of oral manifestations and immunohistochemical profile of epithelial maturation. J Cutan Pathol 2006; 33:657.</a></li><li><a class="nounderline abstract_t">Pennebaker JB, Gilliam JN, Ziff M. Immunoglobulin classes of DNA binding activity in serum and skin in systemic lupus erythematosus. J Clin Invest 1977; 60:1331.</a></li><li class="breakAll">Rothfield N. Clinical features of systemic lupus erythematosus. In: Textbook of Rheumatology, Kelley WN, Harris ED, Ruddy S, Sledge CB (Eds), WB Saunders, Philadelphia 1981.</li><li><a class="nounderline abstract_t">Rahman P, Gladman DD, Urowitz MB. Nasal-septal perforation in systemic lupus erythematosus--time for a closer look. J Rheumatol 1999; 26:1854.</a></li><li><a class="nounderline abstract_t">Sebaratnam DF, Murrell DF. Bullous systemic lupus erythematosus. Dermatol Clin 2011; 29:649.</a></li><li><a class="nounderline abstract_t">Contestable JJ, Edhegard KD, Meyerle JH. Bullous systemic lupus erythematosus: a review and update to diagnosis and treatment. Am J Clin Dermatol 2014; 15:517.</a></li><li><a class="nounderline abstract_t">Izmirly PM, Llanos C, Lee LA, et al. Cutaneous manifestations of neonatal lupus and risk of subsequent congenital heart block. Arthritis Rheum 2010; 62:1153.</a></li><li><a class="nounderline abstract_t">Izmirly PM, Costedoat-Chalumeau N, Pisoni CN, et al. Maternal use of hydroxychloroquine is associated with a reduced risk of recurrent anti-SSA/Ro-antibody-associated cardiac manifestations of neonatal lupus. Circulation 2012; 126:76.</a></li></ol></div><div id="topicVersionRevision">Topic 4666 Version 33.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17060022" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Cutaneous lupus erythematosus: understanding of clinical features, genetic basis, and pathobiology of disease guides therapeutic strategies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23000206" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Cutaneous lupus erythematosus: first multicenter database analysis of 1002 patients from the European Society of Cutaneous Lupus Erythematosus (EUSCLE).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7655105" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Classification of lupus erythematosus based upon cutaneous manifestations. Dermatological, systemic and laboratory findings in 191 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20202590" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Cutaneous lupus and the Cutaneous Lupus Erythematosus Disease Area and Severity Index instrument.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19785596" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Comparative analysis of subacute cutaneous lupus erythematosus and chronic cutaneous lupus erythematosus: clinical and immunological study of 270 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25369985" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Epidemiology of systemic lupus erythematosus and cutaneous lupus erythematosus in a predominantly white population in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19289752" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Incidence of cutaneous lupus erythematosus, 1965-2005: a population-based study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21574972" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Cutaneous lupus erythematosus and the association with systemic lupus erythematosus: a population-based cohort of 1088 patients in Sweden.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15990071" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Subacute cutaneous lupus erythematosus: 25-year evolution of a prototypic subset (subphenotype) of lupus erythematosus defined by characteristic cutaneous, pathological, immunological, and genetic findings.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21910708" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Determining risk factors for developing systemic lupus erythematosus in patients with discoid lupus erythematosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8745897" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Lupus erythematosus profundus: a cutaneous marker for a distinct clinical subset?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20404245" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Tumid lupus erythematosus: a form of lupus erythematosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29788808" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Epidemiology of cutaneous lupus erythematosus and the associated risk of systemic lupus erythematosus: a nationwide cohort study in Denmark.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25071264" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Toxic Epidermal Necrolysis-like Rash of Lupus: A Dermatologist's Dilemma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23761100" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : A case of toxic epidermal necrolysis-like skin lesions with systemic lupus erythematosus and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24238188" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Toxic epidermal necrolysis-like acute cutaneous lupus erythematosus successfully treated with a single dose of etanercept: report of three cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15645750" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Toxic epidermal necrolysis-like acute cutaneous lupus erythematosus and the spectrum of the acute syndrome of apoptotic pan-epidermolysis (ASAP): a case report, concept review and proposal for new classification of lupus erythematosus vesiculobullous skin lesions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17728369" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Toxic epidermal necrolysis-like acute cutaneous lupus erythematosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12664014" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Lupus-associated toxic epidermal necrolysis: a novel manifestation of lupus?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20482683" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Histopathologic manifestations of systemic diseases: the example of cutaneous lupus erythematosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1301986" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Prevalence of acne rosacea in a rheumatic skin disease subspecialty clinic.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/533284" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Subacute cutaneous lupus erythematosus: a cutaneous marker for a distinct lupus erythematosus subset.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18540991" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Pathogenesis of subacute cutaneous lupus erythematosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12814335" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Cutaneous lupus erythematosus: diagnosis and management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10998151" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Association of a promoter polymorphism of tumor necrosis factor-alpha with subacute cutaneous lupus erythematosus and distinct photoregulation of transcription.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18094949" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Pathophysiology of cutaneous lupus erythematosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21564069" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Drug-induced subacute cutaneous lupus erythematosus: evidence for differences from its idiopathic counterpart.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3467658" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Subacute cutaneous lupus erythematosus in multiple members of a family with C2 deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6605148" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Homozygous C2 deficiency, lupus erythematosus, and anti-Ro (SSA) antibodies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12224978" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Frequency and severity of systemic disease in patients with subacute cutaneous lupus erythematosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12170873" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Cutaneous lupus erythematosus: a review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24423191" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Lupus erythematosus. Part II: clinical picture, diagnosis and treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22458771" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Subacute cutaneous lupus erythematosus and its association with drugs: a population-based matched case-control study of 234 patients in Sweden.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12533163" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Drug-induced, Ro/SSA-positive cutaneous lupus erythematosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11559217" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Subacute cutaneous lupus erythematosus induced or exacerbated by terbinafine: a report of 5 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18797894" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Drug-induced subacute cutaneous lupus erythematosus: a paradigm for bedside-to-bench patient-oriented translational clinical investigation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30763648" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Are there distinct clinical and pathological features distinguishing idiopathic from drug-induced subacute cutaneous lupus erythematosus? A European retrospective multicenter study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22004879" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Tissue eosinophilia: not an indicator of drug-induced subacute cutaneous lupus erythematosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10981645" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : The spectrum of cutaneous manifestations in lupus erythematosus--the Italian experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7229150" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Distinctive cutaneous subsets in the spectrum of lupus erythematosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1570517" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Cutaneous lupus erythematosus without systemic lupus erythematosus: clinical and laboratory features.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23541758" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Association of discoid lupus erythematosus with other clinical manifestations among patients with systemic lupus erythematosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27230554" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Early discoid lupus erythematosus protects against renal disease in patients with systemic lupus erythematosus: longitudinal data from a large Latin American cohort.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24477339" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Systemic symptoms in the progression of cutaneous to systemic lupus erythematosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4102091" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Laboratory abnormalities in the diagnosis and management of lupus erythematosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3871800" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Systemic lupus erythematosus in patients with chronic cutaneous (discoid) lupus erythematosus. Clinical and laboratory findings in seventeen patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31120600" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Time to progression from discoid lupus erythematosus to systemic lupus erythematosus: a retrospective cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22782164" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Autoantibody and clinical profiles in patients with discoid lupus and borderline systemic lupus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32584927" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Creation and Validation of Classification Criteria for Discoid Lupus Erythematosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21163152" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Hypertrophic discoid lupus erythematosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30030152" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Chronic Inflammation Promotes Skin Carcinogenesis in Cancer-Prone Discoid Lupus Erythematosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10926740" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Lupus erythematosus tumidus--a neglected subset of cutaneous Lupus erythematosus: report of 40 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25411260" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Smoking is highly associated with discoid lupus erythematosus and lupus erythematosus tumidus: analysis of 405 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12910555" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Tumid lupus erythematosus: criteria for classification with immunohistochemical analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19712116" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Lupus erythematosus tumidus is a separate subtype of cutaneous lupus erythematosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9918242" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Lupus panniculitis: clinical perspectives from a case series.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2671535" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Lupus erythematosus panniculitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22669997" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Lupus mastitis: a mimicker of breast carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11168747" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : The cutaneous pathology of lupus erythematosus: a review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19195975" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Subcutaneous panniculitis-like T-cell lymphoma: redefinition of diagnostic criteria in the recent World Health Organization-European Organization for Research and Treatment of Cancer classification for cutaneous lymphomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11388094" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Clinical and histopathologic features and immunologic variables in patients with severe chilblains. A study of the relationship to lupus erythematosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1558991" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Chilblain lupus erythematosus: report of 15 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/326194" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Unusual variant of lupus erythematosus or lichen planus. Clinical, histopathologic, and immunofluorescent studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7142458" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Coexistence of lichen planus and systemic lupus erythematosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23761099" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Lupus erythematosus/lichen planus overlap syndrome: successful treatment with acitretin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11712024" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Immunofluorescence in dermatology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6989372" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : The specificity and clinical usefulness of the lupus band test.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7751090" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Diagnostic evaluation of the lupus band test in discoid and systemic lupus erythematosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2064397" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Twenty percent of biopsy specimens from sun-exposed skin of normal young adults demonstrate positive immunofluorescence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7962822" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Occurrence of positive immunofluorescence in the dermo-epidermal junction of sun-exposed skin of normal adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28112801" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Efficacy and comparison of antimalarials in cutaneous lupus erythematosus subtypes: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30758479" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Assessment of Antimalarial Therapy in Patients Who Are Hypersensitive to Hydroxychloroquine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26850655" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : The effect of increasing the dose of hydroxychloroquine (HCQ) in patients with refractory cutaneous lupus erythematosus (CLE): An open-label prospective pilot study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22508872" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Low blood concentration of hydroxychloroquine in patients with refractory cutaneous lupus erythematosus: a French multicenter prospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21844448" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Successful treatment of subacute lupus erythematosus with ustekinumab.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22438028" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Response to ustekinumab in a patient with both severe psoriasis and hypertrophic cutaneous lupus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25486913" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Treatment of coexistent psoriasis and lupus erythematosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23134988" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Apremilast for discoid lupus erythematosus: results of a phase 2, open-label, single-arm, pilot study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35118185" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Oral tofacitinib citrate for recalcitrant cutaneous lupus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26916391" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : JAK1/2 Inhibitor Ruxolitinib Controls a Case of Chilblain Lupus Erythematosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25707733" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Brief report: responses to rituximab suggest B cell-independent inflammation in cutaneous systemic lupus erythematosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30383114" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Assessment of Response to B-Cell Depletion Using Rituximab in Cutaneous Lupus Erythematosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30383114" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Assessment of Response to B-Cell Depletion Using Rituximab in Cutaneous Lupus Erythematosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30383114" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Assessment of Response to B-Cell Depletion Using Rituximab in Cutaneous Lupus Erythematosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7357763" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Circulating immune complexes in patients with necrotizing vasculitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16609348" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Vasculitis in systemic lupus erythematosus: Prevalence and clinical characteristics in 670 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16609348" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Vasculitis in systemic lupus erythematosus: Prevalence and clinical characteristics in 670 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4841259" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Lupus hair.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/739493" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Nail lesions in systemic lupus erythematosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10459116" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Lupus erythematosus-associated red lunula.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24809890" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Papulonodular mucinosis in a patient with systemic lupus erythematosus and antiphospholipid syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12100703" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Multiple eruptive dermatofibromas in patients with systemic lupus erythematosus treated with prednisone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/623694" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Oral mucosal ulceration in systemic lupus erythematosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6366226" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Oral mucosal lesions in systemic lupus erythematosus--a clinical, histopathological and immunopathological study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17026516" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Lupus erythematosus: clinical and histopathological study of oral manifestations and immunohistochemical profile of epithelial maturation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/334800" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Immunoglobulin classes of DNA binding activity in serum and skin in systemic lupus erythematosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/334800" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Immunoglobulin classes of DNA binding activity in serum and skin in systemic lupus erythematosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10451095" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Nasal-septal perforation in systemic lupus erythematosus--time for a closer look.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21925012" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Bullous systemic lupus erythematosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25358414" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Bullous systemic lupus erythematosus: a review and update to diagnosis and treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20131261" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Cutaneous manifestations of neonatal lupus and risk of subsequent congenital heart block.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22626746" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Maternal use of hydroxychloroquine is associated with a reduced risk of recurrent anti-SSA/Ro-antibody-associated cardiac manifestations of neonatal lupus.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
